Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Congressional Testimony

Congressional Testimony

                        Congressional Testimony 2018 - 2019
          Congressional Testimony  2017
          Congressional Testimony 2016 Home
          News & Events
          Congressional Testimony
          Preparing for and Responding to Future Public Health Risks - 05/11/2023Congressional Testimony Testimony
    Event Title
              Preparing for and Responding to Future Public Health Risks


                  May 11, 2023

  

    
  Share
    Post
    Linkedin

    Email
    PrintTestimony of 
                    
          Robert M. Califf, M.D., MACC   

 




Introduction

Chairs McMorris Rodgers and Guthrie, Ranking Members Pallone and Eshoo, and distinguished members of the Committee, thank you for the opportunity to testify before you to discuss the Food and Drug Administration’s (FDA’s or the Agency’s) efforts to prepare for the 2023 reauthorization of the Pandemic and All Hazards Preparedness Act.

The Department of Health and Human Services (HHS) had to overcome real challenges while responding to the once-in-a-century COVID-19 pandemic and other recent emergencies, including the infant formula shortage, mpox, and Hurricanes Ian and Fiona.  Similar challenges in the future will be even harder to effectively address without appropriate additional authorities, flexibilities, and funding as requested in the FY 2024 President’s Budget. Together, the proposals my colleagues and I will discuss today will help bridge key gaps and barriers to enable a robust and timely response to future emergencies—by enhancing early detection; safe, effective, and accessible Medical Countermeasures and other supplies; response and health system capacity; and recovery and other supports. These proposals complement the discretionary funding and $20 billion mandatory funding requested across HHS public health agencies to prepare for biological threats.

The last three years of the COVID-19 pandemic underscore the need to continue to optimize our preparedness and response capabilities. The Agency’s continued preparedness for, and capabilities to respond to, public health emergencies and disease threats such as COVID-19, mpox, respiratory syncytial virus, and pandemic influenza have been strengthened by Congress’ support of our work. Our efforts are in close coordination and collaboration with our partners, both within HHS and across the federal government, to help facilitate the development, authorization, licensure, approval, clearance, and availability of critical, safe, and effective medical products and help ensure the continuity of the food supply to address current and future public health threats. We look forward to continuing work with you this Congress to ensure future readiness.

Click for full version of testimony.

                                                                                  Content current as of:
      05/11/2023More Congressional
      Testimonies

        
        Congressional Testimony

          
                        Congressional Testimony 2018 - 2019
          Congressional Testimony  2017
          Congressional Testimony 2016
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop